A phase 2 trial of FOLFIRINOX in patients with previously untreated metastatic pancreatic cancer
Phase 2
- Conditions
- previously untreated pancreatic cancer
- Registration Number
- JPRN-jRCT2080221426
- Lead Sponsor
- Yakult Honsha Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma
-ECOG performance status (PS) :0-1
-Metastatic disease with measurable lesion based on RECIST criteria
Exclusion Criteria
-Prior treatment with chemotherapy or radiotherapy
-Synchronous or metachronous cancer
-Serious concomitant disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression free survival, overall survival, safety